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Regulation  of  92-kD  Gelatinase  Release  in  HL-60  Leukemia  Cells:  Tumor 
Necrosis  Factor-a!  as  an  Autocrine  Stimulus  for  Basal-  and  Phorbol 
Ester-Induced  Secretion 
By Christian Ries, Helmut Kolb, and Petro E. Petrides 
Matrix metalloproteinase 9 ("P-9). also known as  92-kD 
type IV collagenaselgelatinase, is believed to  play a critical 
role in tumor invasion  and metastasis. Here, we  report  that 
MMP-9 was constitutively released from  the human promy- 
elocflic cell line HL-60  as determined by zymographic analy- 
sis. Tumor necrosis factor-a (TNF-a) enhanced the enzyme 
release threefold to  fourfold  and  the  protein kinase C (PKC) 
activator and differentiation inducer 12-0-tetradecanoyl- 
phorbol-13-acetate (TPA) eightfold to  ninefold. Gelatinase 
induction  by TNF-a and TPA was inhibited  by actinomycin 
D or cycloheximide, indicating that de novo protein synthe- 
sis was required. Neutralizing monoclonal antibodies to  
TNF-a (anti-TNF-a) decreased the basal MMP-9 release of 
these cells. In addition, these antibodies also significantly 
interfered with the TPA-induced enzyme release. Agents 
that inhibit TNF-a expression in HL-60  cells, such as pentoxi- 
fylline and dexamethasone, completely abrogated both  the 
constitutive and TPA-evoked MMP-9 release. Diethyldithio- 
CUTE MYELOID LEUKEMIA is not only character- 
ized by a genetically determined disturbance of prolif- 
eration and differentiation of immature progenitor cells but 
also by  an altered egress of these cells from the bone  marrow 
(BM). Acute leukemia can serve as a paradigm for metastasis 
in general, because for cancer cells to leave primary  tumor 
and to form metastatic colonies they must also be able to 
cross matrix barriers and penetrate blood vessel walls.' These 
traffics depend on the catalytic modification of extracellular 
matrix and basement membranes that are mediated by matrix 
metalloproteinases (MMPs), a family of structurally and 
functionally related proteolytic enzymes. Among them, two 
enzymes with molecular weight of 72 kD (MMP-2) and 
92 kD ("P-9) are subclassified as type IV collagenases/ 
gelatinases. They digest denatured collagens (gelatins), in- 
tact type IV basement membrane collagen, native collagen 
type V, and also fibronectin and laminin. Gelatinases are 
thought to play a critical role in the process of invasion and 
metastasis, because a strong correlation between type IV 
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carbamate, which  is  known to  stimulate TNF-a production 
in HL-60  cells, exerted a positive effect on MMP-9 release in 
untreated cells but was inhibitory in TPA-treated HL-60 cells. 
The PKC inhibitor staurosporine at  low concentrations (100 
ng/mL) caused  a significant  augmentation of MMP-9 release 
in untreated  cultures that was blocked by  the  addition  of 
anti-TNF-a. High concentrations (2  NmollL) of stauro- 
sporine completely abolished the extracellular enzyme activ- 
ity both in untreated and TPA-stimulated cells.  These results 
suggest, that TNF-a is required for basal and PKC-mediated 
MMP-9 release in HL-60 leukemia cells. Thus, MMP-9 secre- 
tion may be regulated by TNF-a not  only in a paracrine but 
also in an autocrine fashion. This may potentiate  the  matrix 
degradative capacity of  immature leukemic cells in the pro- 
cesses of bone marrow egress and the evasion of these cells 
into peripheral tissue. 
0 1994 by The American  Society of Hematology. 
collagenolytic/gelatinolytic activity and metastatic potential 
has been shown for various human tumor cell linesz4 Type 
IV collagenase is associated with the invading cancer cells 
of invasive colon, breast, and renal cell carcinomas but is 
not associated with adjacent normal m ~ c o s a . ~ - ~  Moreover, in 
plasma of patients with breast and colon cancer, significantly 
increased levels of 92-kD gelatinase were determined, sug- 
gesting this enzyme as a useful additional marker for the 
dissemination of certain types of cancer.' 
The regulation of MMPs is complex and occurs at differ- 
ent levels. At the posttranslational level, proteolytic activity 
is mainly regulated by the extracellular conversion of the 
inactive proenzyme into the active enzyme and by the inter- 
action with  specific tissue inhibitors of matrix metalloprotei- 
nases. MMP expression is influenced by a variety of biologic 
active agents such as growth factors, cytokines, and tumor 
promoters in various ways at the transcriptional level. In- 
terleukin- 1 (IL-l), tumor necrosis factor-a  (TNF-a), epider- 
mal growth factor (EGF), and the phorbol ester 12-0-tetra- 
decanoylphorbol-l3-acetate (TPA) have been found to be 
inducers of 92-kD gelatinase in  many cell Whereas 
transforming growth factor$ (TGF-P), dexamethasone, and 
retinoic acid are all known  to downregulate the expression 
of interstitial collagenase (MMP-1) and stromelysin (MMP- 
3),I3-l5 TGF-P can stimulate the secretion of the two gela- 
tinases MMP-2 and MMP-9.'6,'7 
In the present report, we investigated the influence of 
TNF-a, monoclonal antibodies (MoAbs) against TNF-a, 
TNF-a-expression modifiers, and protein kinase C (PKC) 
modulators on the release of 92-kD type IV collagenase/ 
gelatinase (MMP-9) in the human promyelocytic cell line 
HL-60. 
MATERIALS AND METHODS 
Reagents. All chemical reagents were purchased from Sigma 
(Munich, Germany). Recombinant human TNF-a (rhTNF-a) and an 
IgG MoAb to TNF-a were gifts from Knoll AG (Ludwigshafen, 
Germany); rhIL-la was provided by Hoffmann La Roche (Grenz- 
ach-Wylen, Switzerland); rhIL-3 was from Amgen (Thousand Oaks, 
Blood, Vol83, No 12 (June 15), 1994 pp 3638-3646 
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CA); rhL-6 was obtained from Boehringer (Mannheim, Germany); 
native murine L - 9  was a gift from Dr Hiiltner (GSF, Munich, Ger- 
many); rh granulocyte-macrophage colony-stimulating factor 
(rhGM-CSF) was from Sandoz (Basel, Switzerland); rh granulocyte- 
CSF (rhG-CSF) was from Genetics Institute (Cambridge, MA); re- 
combinant murine mast cell growth factor (MGF; c-kit ligand) was 
provided by Immunex (Seattle, WA); and rhEGF was obtained from 
Chiron CO (Emeryville, CA). 
Cell culture. HL-60 cells (American Type Culture Collection, 
Rockville, MD) were cultured under serum-free conditions in Is- 
cove's Modified Dulbecco Medium supplemented with 5 pg/mL 
transferrin and 0.5 pg/mL insulin. Cells were routinely passaged in 
25-cm2 flasks (Falcon, San Diego, CA) with medium changes once 
or twice a week. Cultures were evaluated for mycoplasma contami- 
nation every 3 months. Viability of cells was determined using the 
trypan-blue exclusion test and the methylthiotetrazole assay." Cell 
numbers were either counted under the microscope or electronically 
with a Coulter Counter (Coulter Electronics Inc, Hialeah, FL). After 
incubation with TPA, adherent cells had to be detached by treatment 
with trypsin before counting. 
Cell incubation assay. To determine the production of gela- 
tinase, cells were seeded at 1.0 to 1.8 X 106/mL in 96- or 24- 
well microtiter plates (Nunc, Roskilde, Denmark) and treated with 
different agents. After an incubation period of 24 or 48 hours (as 
indicated in the text), cells were removed by centrifugation, and 
culture supernatants (250 pL in 96-well plates and 1 mL in 24-well 
plates) were subsequently analyzed. 
Zymographic analysis and quantification of gelatinase. Gela- 
tinase activity in cell culture supernatants was determined by zymog- 
raphy with sodium dodecyl sulphate polyacrylamide gel electropho- 
resis (SDS-PAGE; LKBPharmacia, Uppsala, Sweden). This 
technique was performed on horizontal ultrathin gels (125 X 250 X 
0.5 mm) with a 6% to 20% (wtlvol) polyacrylamide gradient. Gels 
were prepared and polymerized on GelBond PAG film (FMC, Rock- 
land, ME) according to  the method of Gorg et all9 and Schickle et 
al." with the modification that gelatin type I at a final concentration 
of 1.5 mg/mL was added and copolymerized. Samples were run 
under nonreducing conditions without prior boiling. After electro- 
phoresis, gels were washed 3 times for 20 minutes in  2% Triton X- 
100 to remove SDS and to allow proteins to renature. The gels were 
then immersed in buffer containing 50 mmoVL TRIS pH 7.5, 5 
mmoVL CaCI,, 1 pmoVL ZnCl,, and 0.01% (wt/vol) NaN, for 24 
to  48 hours at 37°C. The zymograms were stained with 0.4% (wtl 
vol) Coomassie Blue and destained in 35% ethanol/lO% acetic acid. 
Clear zones of gelatin lysis against a blue background stain indicated 
enzyme activity. Quantitative determination of gelatinase activity 
was achieved by one-dimensional laser scanning densitometry 
(PharmaciaLKB) of the stained zymograms. Activity was expressed 
in absolute scanning units, representing the integration value of  both 
brightness (in absorption units) and width (in square millimeters) of 
substrate lysis zones or was converted to relative activity in percent 
of the control. The values of enzyme activity determined by zymo- 
graphic analysis actually represent the total amount of secreted 
MMP-9, because this technique allows the gelatinase to be separated 
from potentially cosecreted inhibitors during electrophoresis. Subse- 
quent treatment with Triton X-100 leads to an regeneration of proteo- 
lytic activity together with an activation of latent proenzymes in the 
gel. 
Cell extraction. After treatment with different drugs for  48 
hours, cells were separated from conditioned media by centrifuga- 
tion. Cell pellets were washed in a buffer containing 50 mmol/L 
TRIS pH 7.5, 5 mmoVL CaC12, and 1 pmoVL ZnC1, and were 
subsequently treated with this buffer containing 1% Triton X-100 
and 1 mmoVL phenylmethylsulfonyl fluoride until more than 95% 
Of the cell plasma membranes were disrupted as monitored by phase 
microscopy. The supernatants were collected after centrifugation at 
12,000g and analyzed for gelatinolytic activity by zymography. For 
control, the corresponding media containing extracellular activity 
were treated in the same manner. 
Determination of TNF-a antigen by enzyme-linked immunosor- 
bunt assay (ELISA). TNF-(r antigen was measured in cell culture 
supernatants using a sandwich ELISA with a MoAb to TNF-a pro- 
vided by Knoll AG that was the same as for the neutralizing experi- 
ments. The detection limit was 4 pg/mL. 
RESULTS 
Influence of various cytokines and differentiation inducers 
on 92-kD gelatinase release, cell morphology, and cell num- 
ber. When HL-60 cells were cultured  under  serum-free 
conditions, they constitutively released  92-kD type IV 
collagenase/gelatinase ("P-9) into the medium as deter- 
mined by zymographic analysis (Fig 1A). Incubation with 
TNF-a (100 ng/mL) or TPA (100 ng/mL)  resulted  in  a three- 
fold to fourfold or eightfold to ninefold increase of gelatinase 
activity per cell in 48-hour culture fluids when compared 
with  untreated control (Fig  1A  and  B). Cell morphology was 
changed towards the adherent type by treatment  with TPA 
after  24 to 48 hours, whereas no morphologic changes during 
the incubation time were observed with TNF-CY. Counting 
of cells indicated that  maximal  stimulatory doses of TNF-a 
had no influence on absolute cell number when compared 
with untreated cultures. Determination of cell numbers in 
cultures treated with TPA after trypsinization of adherent 
cells indicated an arrest in cell division, because cell numbers 
remained  unchanged  after addition of TPA over an incuba- 
tion  period of 48 hours (data not  shown). This shows that 
TNF-a and  TPA increased the yields of gelatinase generated 
by the individual cell. 
In contrast, addition of IL-la  (l00 to 500 U/mL), IL-3 
(100 to 750 ng/mL), IL-6 (10 to 20 U/mL), IL-9 (10 to 20 
U/mL), MGFlc-kit ligand (100 to 500 ng/mL), EGF (100 to 
750 ng/mL), concanavalin A (50 to 250 pg/mL), or bacterial 
lipopolysaccharide (LPS; 10 to 50 pg/mL) had  no  or  only  a 
small effect (< 15% over control) on  the  secretion of 92-kD 
gelatinase (data  not shown). 
Analysis of TNF-a- and TPA-induced 92-kD gelatinase 
release. TPA was more effective than TNF-a, with a half 
maximal stimulation at 5 ng/mL  or 75 ng/mL,  respectively 
(Fig 2A). At optimal stimulatory concentrations of TNF-CY 
or TPA, cumulative release of 92-kD gelatinase was ob- 
served for at  least 72 hours,  with  a  maximal  production  rate 
between 6 and 24 hours both with TNF-CY or TPA (Fig 
2B). This stimulation of enzyme secretion was completely 
abolished on incubation  with either actinomycin  D (10 pg/ 
mL) or cycloheximide (10 pg/mL), both inhibitors of cellular 
protein synthesis (Fig 2B). Treatment of HL-60 cells with 
the nontumor-promoting TPA analogue, 4-a-phorbol 12,13- 
didecanoate (4-a-TPA; 1 to 100 ng/mL),  which is able nei. 
ther to activate PKC nor to induce cellular differentiation, 
failed to stimulate "P-9 release (data not  shown). 
To compare  the level of cell-associated and  released  gela- 
tinase activity, cells were incubated  with  TPA (100 ng/mL) 
or TNF-a (100 ng/mL) for 48 hours.  When cell extracts and 
supernatants were tested for the presence of gelatinolytic 
activity by zymography, no cell-associated activity could 
U/mL), GM-CSF (100 to 750 U/&), G-CSF (100 to 750 
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Fig 1. Basal and stimulated release of 92-kD gelatinase from HL- 
60 cells is shown. After  incubation with TNF-a (100 ng/mL)  or TPA 
(l00 ng/mL)  for 48 hours, cell number was determined, and condi- 
tioned media was analyzed by SDS-PAGE zymography and compared 
with untreated  control (A). The light areas that represent zones of 
lysis in  the gelatin  gel  were  quantitated  by laser scanning densitome- 
try.  Activity  is expressed in units of activity per volume  and per cell, 
relative to  the basal enzyme release of untreated  control (B). Results 
from a representative determination are shown. Similar  results  were 
obtained in four separate experiments. 
be detected, whereas the culture supernatants showed 100% 
MMP-9 activity (data not shown). 
Inhibition of basal and TPA-induced release of 92-kD 
gelatinase by neutralizing TNF-a antibodies. Addition of 
RIES, KOLB, AND PETRIDES 
an MoAb against TNF-a (anti-TNF-a) caused a dose-de- 
pendent decrease of the  basal 92-kD gelatinase release  into 
the culture supernatant of unstimulated HL-60 cells (Fig 3). 
Inhibitory concentrations of anti-TNF-a did not alter cell 
growth and viability (data not shown). This antibody also 
blocked  the TNF-a-induced increase of gelatinase produc- 
tion, showing its neutralizing effect. Moreover, anti-TNF- 
a almost completely abolished TPA-induced release of 92- 
kD gelatinase activity (Fig 3). 
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Fig 2. Dose-response curve and  time course of stimulated MMP- 
9 release from HL-60 cells is shown. Cultures were  treated  for 48 
hours with different doses of TPA or TNF-a, and supernatants were 
analyzed for 92-kD gelatinase by zymography and scanning densi- 
tometry (A). HL-60 cells were incubated with a maximal  stimulatory 
concentration of TPA (100 ng/mL) or TNF-a (100 ng/mLl with or 
without  actinomycin D (AMD; 10 pg/mL)  or cycloheximide (CHX; 10 
pg/mL).  Aliquots  were  taken  at  different  time  intervals and analyzed 
for gelatinase content (B). Results are the mean of duplicate experi- 
ments and expressed in absolute scanning units. 
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Fig 3. Effect of anti-TNF-a on basal and stimulated release  of 92- 
kD gelatinase is shown. HL-60  cultures, unstimulated or stimulated 
with TNF-a (100 ng/mL) or TPA (100 nglmLI,  were incubated with 
anti-TNF-a (10 or 100 pg/mL) for  48 hours. Gelatinase release into 
conditioned media was quantitated by zymographic  analysis  as de- 
scribed. Results are expressed in percentage of the basal enzyme 
level of untreated cultures. Mean values  of two separate experiments 
are shown. 
Modulation of basal 92-kD gelatinase secretion by TNF- 
a-expression modifiers and an inhibitor of PKC. Pentox- 
ifylline and dexamethasone, which inhibit TNF-a transcrip- 
tion  a d translation in HL-60 caused a significant 
dose-dependent decrease in extracellular 92-kD gelatinase 
activity in HL-60 cells as determined by zymographic analy- 
sis. Pentoxifylline (5 mmol/L) or dexamethasone (100 pmoV 
L) completely blocked the release of this enzyme (Fig 4A 
and B). Treatment with diethyldithiocarbamate (DDTC) that 
stimulates TNF-a gene expression in HL-60 cells" resulted 
in a threefold to fourfold increase in 92-kD gelatinase (Fig 
4C). Staurosporine, a potent inhibitor of PKC was tested 
over a concentration range from 0.01 to 1000 nmol/L. Con- 
centrations below 1 nmol/L had only a slight stimulatory 
effect on 92-kD gelatinase release; higher levels caused a 
fourfold increase with a maximum at 100 nmol/L. However, 
at higher concentrations, a dramatic decrease in gelatinolytic 
activity occurred. Incubation with 2 pmol/L staurosporine 
completely abolished 92-kD gelatinase production (Fig 4D). 
Changes in TNF-a release under these experimental con- 
ditions could not be determined, because TNF-a antigen in 
culture supernatants of noninduced HL-60 cells was below 
the detection limit (4 pg/mL) of the ELISA (data not shown). 
However, addition of MoAbs to TNF-a (100 pg/mL) 
blocked the stimulatory effect of  both DDTC (200 pmol/L) 
or staurosporine (100 ng/mL) on gelatinase release, indicat- 
ing the involvement of TNF-a in these effects (Fig 5). 
Pentoxifylline and dexamethasone at maximal inhibitory 
concentrations had no significant influence on absolute cell 
number  and cell viability compared with that for untreated 
cultures after a 48-hour incubation period, whereas stauro- 
sporine (1 pmol/L) reduced viability to about 70% of control. 
DDTC (500 pmol/L) also caused a decrease to about 70% of 
3641 
the control in cell proliferation but simultaneously elevated 
gelatinase release (data not shown). 
To examine potential direct effects on the activity of the 
92-kD enzyme itself, zymograms were incubated with incu- 
bation buffer in the presence of these agents. No alteration 
on gelatinolytic activity could be observed with  any of the 
four drugs, indicating that there is neither a direct activating 
nor inhibiting influence on the enzyme itself (data not 
shown). 
Infiuence of pentoxifylline, dexamethasone, DDTC, and 
staurosporine on TNF-a release, gelatinase secretion, and 
cell number in TPA-stimulated cells. Pentoxifylline or 
dexamethasone caused a downregulation of TPA-evoked 92- 
kD activity in a dose-response-dependent fashion as deter- 
mined by SDS-PAGE zymography (Fig 6A and B). Low 
concentrations of staurosporine augmented TPA-stimulated 
gelatinase release slightly, whereas high concentrations 
showed an inhibitory effect (Fig 6D). In contrast to the find- 
ings with nonstimulated HL-60 cells, exposure to DDTC 
inhibited gelatinolytic activity in TPA-treated cultures (Fig 
6C). 
Determination of TNF-a antigen in supernatants of cul- 
tures treated with TPA (100 ng/mL) alone for 48 hours 
showed that the release of TNF-a from these cells was dra- 
matically elevated compared with  that for untreated control 
(Table l). Coincubation with pentoxifylline, dexamethasone, 
DDTC, or staurosporine in concentrations that  inhibited the 
TPA-stimulated secretion of 92-kD gelatinase also caused a 
significant decrease in extracellular TNF-a protein. In the 
presence of the PKC inhibitor, staurosporine, no TNF-a was 
detectable (Table 1). 
In measuring viability and cell number of TPA-treated 
cells incubated with the different drugs, we found no  signifi- 
cant inhibitory influence with pentoxifyllin (5 mmol/L) and 
dexamethasone ( 1  mmoVL), but some decrease to 65% in 
proliferation with DDTC (1 mmol/L) compared with  that for 
the TPA control was found (Table 1). Cell counts in cultures 
simultaneously treated with TPA and a gelatinase inhibitory 
concentration of staurosporine (1 pmol/L) were  nearly 
equivalent to those in non-TPA-treated cultures without  ad- 
ditive after an incubation period of 48 hours, indicating that 
staurosporine neutralized the TPA-mediated arrest in cell 
division (Table 1). 
DISCUSSION 
In the present study we  used the promyelocytic leukemia 
cell line HL-60 as  a model for a disseminating hematologic 
malignancy. Under serum-free conditions, we found that 
these cells constitutively release a gelatinase with  an appar- 
ent molecular weight of 94-kD into the culture supernatant, 
as determined by gelatin SDS-PAGE. The basal release of 
this enzyme was markedly augmented by TNF-a and TPA. 
Davis et a124 previously described purification  and  identifica- 
tion of a 94-kD gelatinase from TPA-stimulated HL-60 cells 
as 92-kD type IV collagenase/gelatinase (MMP-9). 
TNF-a-  or TPA-evoked secretion of gelatinase was com- 
pletely abolished by the addition of actinomycin D or cyclo- 
heximide, agents that inhibit protein synthesis at the level 
of transcription or translation. This indicates that continuous 
synthesis of RNA  and protein is required  and that the effects 
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Fig 5. Inhibition  of DDTC- and staurosporine-stimulated 92-kD gel- 
atinase secretion by anti-TNF-a is shown. Cells were  incubated with 
stimulatory doses of DDTC (200 pmollLl or staurosporine (l00 ng l  
mLI alone or together with anti-TNF-a (100 pglmL) for 48 hours. 
Supernatants were analyzed by zymography. Enzyme activity  was 
expressed in units  of  activity  relative t o  the basal gelatinase of  the 
untreated  control. Results shown are the  data  of a single experiment 
representative of three so performed. 
Fig 4. Modulation  of basal 
92-kD gelatinase production in 
HL-60 cells by TNF-a-expression 
modifiers  and a PKC inhibitor  is 
shown. Cultures were  incubated 
with or without pentoxifylline 
(A), dexamethasone (B), DDTC 
(C), or staurosporine (D) at  differ- 
ent concentrations for 48 hours 
and  then analyzed for gelatinase 
content in culture  fluids  by zy- 
mography and laser scanning 
densitometry. The graphs show 
the mean values of two  separate 
experiments performed. 
are not because of the release of presynthesized gelatinase 
from granules. This was confirmed by the observation that 
no gelatinolytic activity could be found in cell extracts of 
untreated or stimulated HL-60 cells. Moreover, terminally 
differentiated human neutrophils that store 92-kD gelatinase 
in specific granules release gelatinase very rapidly after treat- 
ment with TPA or TNF"U.'~.'' Maximal activity is usually 
observed within 30 to 60 minutes after incubation with TPA, 
as determined by zymography.'5  On the contrary, in HL-60 
cells, enzyme release was only detectable after 6 hours of 
incubation with TPA or TNF-a. Maximal activity was 
reached after an incubation period of about 72 hours. This 
suggests that TPA as well as TNF-a stimulate HL-60 cells 
to produce gelatinase by de novo synthesis, probably via 
initiation of cellular maturation. TPA induces monocytic/ 
macrophage-like differentiation and activation of PKC in 
HL-60  Incubation  with 4-a-TPA, an analogue that 
does not activate PKC or induce differentiation, had  no stim- 
ulatory effect on gelatinase release. In addition, coincubation 
of TPA-stimulated HL-60 cells with staurosporine, an inhibi- 
tor of  PKC. neutralized the arrest in cell  division  and  blocked 
the augmentation of extracellular TNF-a and gelatinase 
caused by TPA alone. These results indicate that the TPA 
stimulatory effect on gelatinase production in HL-60 cells 
is correlated with cellular differentiation and/or  PKC activa- 
tion. Similar to TPA, TNF-a also increases gelatinase pro- 
duction and induces HL-60 cells to differentiate to the mono- 
cytic phenotype." However, differentiation induction with 
TNF-a is  not necessarily accompanied by a loss of prolifera- 
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Fig 6. Modulation of TPA- 
stimulated  gelatinase  release  in 
HL-60  cells  by  TNF-a-expression 
modifiers  and  a  PKC  inhibitor  is 
shown.  Cultures were incubated 
with TPA in a  maximal  stimula- 
tory dosage of l00 ng/mL and 
simultaneously with or without 
pentoxifylline  (A),  dexametha- 
sone (B), DDTC (C), or stauro- 
sporine (D) at different concen- 
trations  for 24 hours.  Gelatinase 
activity in conditioned  media 
was quantitated by densitomet- 
ric analysis of the zymograms. 
Graphs  show the mean  values of 
two separate experiments per- 
formed. 
PENTOXIFYLLINE ( + P A )  
DDTC ( + P A )  
c? 
am 0.l l 
CONCENTRATION W 
tive capacity,3° as supported by our findings. Because a low 
level of TNF-a gene transcription is present in noninduced 
HL-60 cellsz3 and this basal TNF-a expression is signifi- 
cantly enhanced during monocyte differentiation (for exam- 
ple, through induction with TPA3' or TNF-a itselF*), we 
hypothesized that constitutively secreted TNF-a may be re- 
sponsible for the basal gelatinase release. Quantification of 
Table  1.  Effect  of  Pentoxifylline,  Dexamethasone,  DDTC,  and 
Staurosporine  in  TPA-Stimulated HL-BO Cultures  on  Cell  Number 
and the Release  of TNF-a and  92-kD  Gelatinase 
Gelatinase 
Treatment W m L )  (%l x WImL 
TNF-ol Activity Cell No. 
TPA 100 ng/mL 1070 100  1.4 
TPA + pentoxifyllin 5 mmol/L 652 22 1.4 
TPA + dexamethasone 1 mmol/L 761 46 1.3 
TPA + DDTC 500 pnol/L 470  35 0.9 
TPA + staurosporine 1 pmol/L <4 7 2.2 
None 1 4  15  2.4 
HL-60 cells were seeded at 1 x 1O6/mL and treated with  the indicated 
stimulus. After an incubation period of 48 hours number of viable 
cells was  determined  by exclusion of trypan blue. Supernatants were 
tested for the content of TNF-a by ELISA. Gelatinase activity was 
determined by zymography  and expressed in activity per cell relative 
to the enzyme level in cultures treated  with TPA alone, which was set 
100%. The values represent the average of a duplicate experiment. 
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endogenously produced TNF-a in supernatants of untreated 
HL-60 cells is difficult because the amounts of TNF-a re- 
leased by these cells are below the detection limit of the 
ELISA (<4 pg/mL). But when  we  used neutralizing MoAbs 
against TNF-a, we were able to reduce basal MMP-9 activity 
in culture fluids of unstimulated HL-60 cells to about 35%, 
when compared with untreated control. This inhibitory effect 
of anti-TNF-a suggest that the basal MMP-9 release in HL- 
60 is to a large extent regulated by constitutively secreted 
TNF-a which acts in an autocrine manner for the mainte- 
nance of enzyme release. However, even high excess of 
neutralizing antibody did not completely abrogate enzyme 
activity. This may be because of the continuous delivery of 
TNF-a by the cell, a possible intracrine action of TNF-a, 
the limited half-life time of the antibody in culture, or, most 
likely, the other stimulatory contributions to the basal 92- 
kD gelatinase release. To further analyze the role of TNF- 
a as an autocrine stimulus for the production of MMP-9 
in HL-60 cells, several inhibitors and activators of TNF-a 
expression were examined. DDTC inhibits proliferation but 
elevates TNF-a transcription in HL-60 cells.z3 Similarly, 
DDTC in our system also caused some decrease in the cellu- 
lar proliferation rate but simultaneously elicited a significant 
augmentation of the basal gelatinase activity. This indicates 
again the dependence of MMP-9 secretion on cellular TNF- 
a expression. Additional evidence is provided by the obser- 
vation that pentoxifylline and dexamethasone abrogated 
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92-kD gelatinase activity. Both drugs are known to inhibit 
TNF-a expression  in HL-602’  and  other cell  systems. 
Because the gelatinase inducer TPA acts as an activator 
of PKC, we further investigated the significance of PKC 
for the constitutive MMP-9 secretion by incubation with 
staurosporine,  an inhibitor of PKC. Addition of staurosporine 
to HL-60 cultures showed paradoxical effects on enzyme 
activity in the supernatants. At low concentrations, stauro- 
sporine acted as an potent stimulans of gelatinase release; 
at  higher concentrations,  however, it acted  as  an strong inhib- 
itor.  Interestingly,  these  bifunctional effects of  the PKC  mod- 
ulator are  consistent with  the  results  of  Coffey et a13’ who 
found that low levels of staurosporine augmented TNF-a 
release in LPS-RPA-stimulated  human monocytes, whereas 
high  levels of the  PKC inhibitor  prevented LPS-/TPA- 
evoked  TNF-a release. The  molecular basis of this  bifunc- 
tional effect  remains  to be elucidated. 
To determine the role of TNF-a in DDTC- as well as 
staurosporine-enhanced gelatinase release, we analyzed  su- 
pernatants of HL-60  cells treated with stimulatory  concentra- 
tions of these drugs. Detection of extracellular TNF-a anti- 
gen by ELISA  was not  successful, obviously because of the 
low amounts secreted (<4 pg/mL). But indirect evidence  for 
TNF-a as the  cause of the  DDTC-  and staurosporine-medi- 
ated effect was achieved by MoAbs to TNF-a. Addition 
of anti-TNF-a abolished both DDTC- and staurosporine- 
enhanced gelatinase release in HL-60 (Fig 5). Hence, the 
influence  of staurosporine on 92-kD gelatinase  secretion in 
HL-60  is likely to be  caused  by a PKC mediated  modulation 
of TNF-a  expression. 
Anti-TNF-a repressed 92-kD activity  in  TPA-stimulated 
cells  to  about 20% of TPA-control without  antibody. There- 
fore, it is  possible that the autocrine secretory TNF-a  loop 
also participates in the TPA-mediated gelatinase augmen- 
tation. This  assumption  is  supported by the  observation, that 
pentoxifylline and dexamethasone reduced both the TPA- 
evoked augmentation in gelatinase and TNF-a release. In 
contrast to  immature  HL-60  cells, dithiocarbamates  such as 
DDTC downregulate TNF-a expression in mature mono- 
c y t e ~ ’ ~  and in other  cell  systems  by inhibiting  nuclear factor 
K B   a ~ t i v a t i o n . ~ ~  DDTC also caused a strong inhibition of 
both TNF-a and enzyme secretion in TPA-treated  cells.  Low 
concentration  of  the PKC  modulator, staurosporine, did not 
enhance TPA-stimulated enzyme activity to a great extent 
(as was observed in untreated cells), whereas high doses 
completely abolished MMP-9 secretion and  TNF-a release. 
This indicates that TPA, at an optimal stimulatory dosage, 
leads to an activation of PKC resulting in a stimulation of 
TNF-a expression  that induces gelatinase  production,  which 
is downregulated by the inhibition of the kinase at high 
staurosporine concentrations. 
Taken together, our  observations  show  that  MMP-9 pro- 
duction  in untreated and  TPA-induced  leukemic  HL-60  cells 
can be regulated by the modulation of TNF-a expression 
at the transcriptional or posttranscriptional  level in both an 
autocrine and paracrine  fashion. Very little  is known  about 
the regulatory  processes  that govern  the normal or malignant 
egress of white  blood cells  from  the BM.36 Cytokines play 
a central role in the network of interactions among these 
cells and their extracellular matrix. There is no doubt that 
autocrine  circuits  can  be a  critical step in myeloid  leukemo- 
genesis, because  leukemic cells  produce their  own  bioactive 
factors (eg, TNF-a, IL-I, G-CSF, or GM-CSF) that can 
modify growth  and  differentiati~n.’~~~’ But growth stimula- 
tion by itself is not sufficient to  induce  leukemia. Moreover. 
the  autocrine  expression  of cytokines,  as well as factors pro- 
duced from, for example, BM stromal or endothelial cells, 
in a paracrine  manner, may  influence  the  interaction of can- 
cer  cells with  their environment  during the  metastatic  process 
to allow immature  cells  to  leave  the  BM or to  cross vascular 
a is ubiquitously and constitutively expressed in different 
leukemias, with great frequency in samples from patients 
with  acute or  chronic  monocytic leukemias  and chronic 
lymphocytic leukemia.” Moreover, TNF-a levels in serum 
of patients with acute myeloid leukemia were found to be 
significantly increased.44 Furthermore, Ulich et ald5 report 
that injection of TNF-a in rats induced peripheral neutro- 
philia accompanied by a  significant  depletion of BM neutro- 
phils, and that this process was inhibited by the TNF-a- 
expression  inhibitor, dexamethasone.  We have  identified an 
autocrine TNF-a loop in the promyelocytic leukemia cell 
line  HL-60 that is responsible  for  the  continuous release  of 
92-kD  type IV collagenase/gelatinase, an matrix-degrading 
enzyme that is associated  with the invasive and metastasizing 
potential of tumor c e k 2  This loop was also found to be 
involved in the phorbol ester-induced  MMP-9 secretion dur- 
ing monocytic  differentiation.  Moreover, enzyme release 
was stimulated by exogenous TNF-a, implicating also an 
paracrine  regulation mechanism.  Thus,  TNF-a-regulated 
MMP-9 secretion may be one of the important cytokine- 
mediated  effects,  which is possibly  involved  in  the  premature 
egress of leukemic  cells  from the BM. 
bamiers,36.42.43 Recent in vivo  studies have  shown that TNF- 
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